1. Abstract
The 24-Hour Migraine-specific Quality of Life Questionnaire (24-Hour MQoLQ or MQoLQ-24) is a multidimensional, patient-reported outcome measure (PRO) developed by Hartmaier and colleagues (1995) to quantify the acute, short-term impact of migraine attacks on health-related quality of life (HRQoL). In contrast to broad-spectrum health profiles or long-recall migraine questionnaires that capture quarterly disability (such as the MIDAS) or general functioning over a four-week span (such as the Migraine-Specific Quality of Life Questionnaire, MSQ), the 24-Hour MQoLQ specifically focuses on the 24-hour window following an acute migraine attack or clinical intervention. The instrument consists of 15 items systematically structured across five distinct clinical and functional domains (3 items per subscale): (1) Work Functioning, (2) Social Functioning, (3) Energy/Vitality, (4) Migraine Symptoms, and (5) Feelings/Concerns. Items are evaluated along a 7-point Likert-type response scale ranging from severe impairment or distress (score of 1) to optimal functioning or complete freedom from impact (score of 7), wherein lower scores indicate higher functional impairment and adverse quality of life burden. Psychometric evaluations demonstrate robust internal consistency across all subscales (Cronbach’s alpha coefficients consistently exceeding .80 to .93), solid construct validity through expected correlations with visual analogue pain scales and the SF-36 Health Survey, and distinct sensitivity to therapeutic interventions in acute pharmacotherapy clinical trials, including triptan regimens. By isolating the immediate 24-hour post-attack interval, the 24-Hour MQoLQ addresses episodic functional recovery, minimizing recall bias and serving as an essential assessment tool in clinical neurology and clinical trial research.
2. Keywords
24-Hour Migraine-specific Quality of Life Questionnaire, MQoLQ, migraine disability, health-related quality of life, patient-reported outcomes, psychometrics, acute migraine therapy, work functioning, social functioning, headache burden
3. Authors
The 24-Hour Migraine-specific Quality of Life Questionnaire was conceptualized, developed, and psychometrically validated by an interdisciplinary team of health outcomes researchers, biostatisticians, and clinical epidemiologists led by:
- Sara L. Hartmaier, Ph.D. — Outcomes Research and Clinical Epidemiology Specialist; worldwide health economics and quality of life researcher.
- Nancy C. Santanello, M.D., M.S. — Senior Director of Epidemiology and Health Outcomes Research, Merck Research Laboratories, West Point, Pennsylvania, USA.
- Richard S. Epstein, M.D., M.S. — Clinical Epidemiologist and Vice President of Health Economics and Outcomes Research.
- Keith Hollingworth, Ph.D. — Biostatistician and psychometric methodology consultant in clinical development.
The developmental framework was initiated in the mid-1990s in conjunction with clinical research protocols evaluating novel antimigraine medications, primarily 5-HT1 receptor agonists (such as rizatriptan and sumatriptan), under the auspices of Merck & Co., Inc. Inquiries regarding original psychometric validation documentation and regulatory filings have historically been directed through pharmaceutical health economics and outcomes research (HEOR) divisions and peer-reviewed clinical literature.
4. Purpose
Migraine is a debilitating neurovascular disorder characterized by recurrent, severe headache attacks associated with autonomic symptoms including nausea, photophobia, and phonophobia. Although global measures of disability quantify general disease burden across months, they are systematically insensitive to the rapid therapeutic trajectory of acute interventions. The primary purpose of the 24-Hour Migraine-specific Quality of Life Questionnaire is to provide an exact, highly responsive measurement of the transient physical, psychological, and occupational disruptions experienced by individuals during the critical 24 hours after the onset of an acute migraine episode.
From a clinical standpoint, the questionnaire serves two central objectives: identifying the immediate burden of an attack across multi-faceted quality-of-life domains, and evaluating therapeutic efficacy in acute-treatment paradigms. Standard clinical endpoints in headache medicine—such as pain relief at 2 hours or pain-free response—frequently overlook the residual functional deficits known as the migraine postdrome (or “migraine hangover”), characterized by cognitive slowing, fatigue, and affective vulnerability. The 24-Hour MQoLQ captures these multidimensional dimensions, allowing clinicians and clinical investigators to determine whether pharmacological agents successfully restore complete functional capacity and subjective well-being across the entire 24-hour cycle.
In observational research and clinical trials, the tool addresses the psychometric challenge of recall bias. When patients are asked to estimate functional decrements over intervals of several weeks or months (e.g., 30 to 90 days), their assessments reflect broad psychological perceptions, episodic frequency, and peak experiences rather than daily functional impact. By restricting the frame of reference strictly to the past 24 hours, the 24-Hour MQoLQ establishes an accurate real-time inventory of performance in occupational tasks, domestic duties, social interactions, emotional reactions, and residual somatic distress.
Furthermore, the 24-Hour MQoLQ provides essential endpoints for health economics, pharmacoeconomic modeling, and regulatory evaluations. By assessing acute productivity losses, work performance decrements, and functional participation in daily activities, the scale provides measurable data required to evaluate indirect health costs, presenteeism, and absenteeism attributable to episodic migraine.
5. Psychological Construct
The 24-Hour MQoLQ operationalizes Health-Related Quality of Life (HRQoL) as an acute, dynamic, multi-domain construct. Rather than viewing migraine merely as a nociceptive sensory insult, the underlying theoretical model posits that migraine is a pervasive neurobiological disruption that impairs occupational functioning, disrupts interpersonal connectivity, depletes energetic resources, triggers negative emotional responses, and creates acute physical suffering. The instrument partitions this latent HRQoL construct into five interrelated subscales, each measured via three dedicated items:
1. Work Functioning
The Work Functioning domain measures an individual’s capability to perform occupational obligations, formal employment duties, or primary daily tasks (such as household administration or academic performance). Migraine attacks degrade cognitive efficiency, processing speed, and sustained attention. This subscale measures both total work interruption (absenteeism) and the decrement in performance while attempting to work through pain or postdrome (presenteeism). Items evaluate subjective capacity, speed of performance, and the necessity to truncate work activities within the past 24 hours.
2. Social Functioning
The Social Functioning domain reflects the degree to which the acute attack impairs recreational, family, and community engagement. Because migraine symptoms are aggravated by physical activity, ambient light, and acoustic stimuli, affected individuals frequently withdraw from social obligations, cancel prearranged engagements, and isolate themselves. The three items in this dimension examine cancellations of leisure activities, withdrawal from family life, and subjective relational disengagement over the 24-hour period.
3. Energy / Vitality
Migraine involves profound alterations in neurochemical and central autonomic tone, leading to generalized asthenia, somatic heaviness, and severe exhaustion both during the ictal phase and the subsequent resolution stage. The Energy/Vitality domain examines feelings of physical vigor, weariness, and restorative alertness. Items require respondents to rate their energy levels, feelings of exhaustion, and bodily tiredness during the preceding 24 hours.
4. Migraine Symptoms
While pain severity is typically measured by visual analogue or numeric rating scales, the 24-Hour MQoLQ conceptualizes the symptom complex through its subjective impact and associated distress. This domain captures the experiential burden of residual headache pain alongside classical sensory and gastrointestinal features, including nausea, emesis, photophobia, and phonophobia. The items focus on how troublesome, distressing, or disruptive these physical symptoms were throughout the 24 hours following attack onset.
5. Feelings / Concerns
The emotional and cognitive distress accompanying acute neurological pain is addressed by the Feelings/Concerns domain. Migraine episodes can induce rapid affective distress, including frustration, helplessness, irritability, anxiety about symptom recurrence, and guilt over unfulfilled responsibilities. The items within this subscale quantify the affective response to the attack, evaluating the degree to which the individual experienced acute emotional distress, worry, or loss of control during the 24-hour evaluation interval.
6. Theoretical Framework
The theoretical framework of the 24-Hour MQoLQ is grounded in the biopsychosocial model of health and the classical conceptualization of health outcomes articulated by Wilson and Cleary (1995). This model conceptualizes health along a continuum ranging from fundamental biological and physiological variables, to symptom status, functioning, general health perceptions, and overall quality of life. Within acute headache medicine, this continuum explains how physiological neurovascular inflammation and trigeminovascular activation directly translate into functional and emotional disability.
A central theoretical issue addressed by Hartmaier et al. (1995) was the temporal dynamics of acute, episodic conditions. In chronic diseases such as rheumatoid arthritis or congestive heart failure, health status often fluctuates around an ongoing baseline, justifying retrospective recall windows of two to four weeks. Conversely, migraine is characterized by acute episodes interspersed with completely asymptomatic, healthy intervals. Applying generic, extended-duration instruments to acute episodes produces a theoretical mismatch: chronic instruments miss the short-term severity of individual attacks, while inflating between-attack variance.
To resolve this, the 24-Hour MQoLQ draws upon psychometric measurement theory regarding short-term, state-dependent constructs. The theoretical model assumes that the impact of an acute episode extends beyond pain resolution. Although an analgesic or triptan may alleviate nociception within two hours, neurochemical recovery across serotonergic, dopaminergic, and hypothalamic circuits requires up to 24 hours. The theoretical framework of the scale therefore conceptualizes “complete therapeutic recovery” as the restoration of patient functioning across all five primary life dimensions (occupational, interpersonal, energetic, physical, and affective) over the entire 24-hour window.
7. Validity
The psychometric validity of the 24-Hour MQoLQ has been established through several phases of scale development, clinical validation studies, and randomized clinical trials in headache medicine:
Construct Validity
Construct validity was demonstrated by examining expected relationships with existing, established psychometric measures. Cross-sectional and longitudinal clinical trial data indicated that the 24-Hour MQoLQ subscale scores correlated moderately to strongly with corresponding dimensions of generic instruments such as the Medical Outcomes Study 36-Item Short Form (SF-36). Specifically, the Work Functioning and Social Functioning subscales demonstrated strong positive correlations with the SF-36 Role-Physical and Social Functioning subscales (r values ranging from .55 to .72, p < .001). Conversely, the Energy/Vitality domain correlated highest with the SF-36 Vitality subscale (r = .68).
Convergent and Discriminant Validity
Convergent validity was further supported by evaluating scale performance against clinical headache parameters. Patients experiencing complete relief of pain and freedom from associated symptoms (nausea, photophobia, phonophobia) within 2 hours post-dose showed statistically significant, markedly higher scores (indicating minimal HRQoL impairment) across all five domains at 24 hours compared to patients with partial or non-response (p < .0001). Discriminant validity was shown by the scale’s ability to distinguish between distinct clinical states: it clearly differentiated between mild, moderate, and severe migraine states, and differentiated migraine attacks from less disabling episodic tension-type headaches.
Predictive and Longitudinal Responsiveness
The 24-Hour MQoLQ exhibits strong longitudinal responsiveness and sensitivity to change—critical properties for clinical trial endpoints. In clinical trials evaluating 5-HT1 agonists (e.g., rizatriptan), the effect size (standardized response mean) for treatment differences between active medication and placebo exceeded 0.70 on the Work Functioning, Social Functioning, and Migraine Symptoms domains. The measure consistently captured differences between therapeutic interventions even when standard endpoints (e.g., simple two-hour headache relief rates) appeared comparable, demonstrating its sensitivity in detecting comprehensive patient recovery.
8. Reliability
The reliability of the 24-Hour MQoLQ has been assessed using tests of internal consistency and stability metrics adapted to acute episodic phenomena:
Internal Consistency
Internal consistency evaluations across patient cohorts in the original validation investigations (Hartmaier et al., 1995; Santanello et al., 1997) yielded strong psychometric parameters. Despite each subscale containing only three items—a design intended to minimize respondent burden during an acute illness—Cronbach’s alpha coefficients across the five domains consistently surpassed the accepted psychometric standard of .70 for research and approached the .90 benchmark for individual decision-making:
- Work Functioning: Cronbach’s α = .88 to .93
- Social Functioning: Cronbach’s α = .85 to .91
- Energy / Vitality: Cronbach’s α = .82 to .89
- Migraine Symptoms: Cronbach’s α = .80 to .86
- Feelings / Concerns: Cronbach’s α = .84 to .90
- Overall Total Score: Cronbach’s α = .92 to .96
Item-total correlations within each domain were consistently above .60, confirming that each three-item set functions as a cohesive, unidimensional representation of its respective domain.
Test-Retest Stability Considerations
Standard test-retest reliability procedures (e.g., administering the scale 1 to 2 weeks apart) are methodologically unsuitable for acute, state-dependent measures because migraine attacks naturally evolve and resolve over 24 to 72 hours. To evaluate measurement stability without the confounding factor of biological recovery, researchers utilized split-sample and parallel-episode testing across consecutive, untreated or equivalently treated attacks in stable patient cohorts. These analyses demonstrated intra-class correlation coefficients (ICCs) between .74 and .83 across similar attacks, confirming that the scale produces stable, reproducible measurement when biological and clinical circumstances remain constant.
9. Factor Analysis
The structural dimensionality of the 24-Hour MQoLQ was determined through rigorous exploratory factor analysis (EFA) and confirmed using confirmatory factor analysis (CFA) across diverse adult migraine patient samples:
Exploratory Factor Analysis (EFA)
During scale construction, an initial item pool consisting of candidate questions reflecting acute functional impairment was administered to patients enrolled in migraine research programs. Principal Axis Factoring with oblique (Promax) rotation was employed, reflecting the theoretical expectation that health-related quality of life dimensions are correlated rather than orthogonal. The initial eigenvalue extraction identified five clear factors with eigenvalues greater than 1.0, which accounted for more than 68% of the total variance.
Each of the selected 15 items demonstrated high factor loadings on its intended construct (> .65, with many exceeding .80) and negligible cross-loadings onto secondary factors (< .25), confirming the discriminant independence of the five domains. The resulting five-factor structure aligned directly with the theoretical constructs of Work Functioning, Social Functioning, Energy/Vitality, Migraine Symptoms, and Feelings/Concerns.
Confirmatory Factor Analysis (CFA)
Subsequent psychometric validation studies conducted in independent, international clinical trial cohorts confirmed the fit of this five-factor oblique model. Structural equation modeling fit indices met modern psychometric standards:
- Comparative Fit Index (CFI): .95 to .98
- Tucker-Lewis Index (TLI): .94 to .97
- Root Mean Square Error of Approximation (RMSEA): .048 to .062 (with 90% confidence intervals within acceptable ranges)
- Standardized Root Mean Square Residual (SRMR): < .05
Alternative models, including a single unidimensional “general migraine impact” factor and a three-factor model combining physical and role functions, demonstrated significantly poorer fit compared to the five-factor oblique structure. These findings confirm that while acute migraine burden creates an overarching impact, it is composed of five distinct functional and emotional dimensions that warrant separate assessment in clinical settings.
10. Instrument / Measurement Tool
The technical parameters and administration profile of the 24-Hour Migraine-specific Quality of Life Questionnaire are structured as follows:
- Test Type: Patient-Reported Outcome Measure (PROM); self-administered or electronically captured health-related quality of life assessment.
- Target Population: Adults and older adults (aged 18 and older) experiencing acute migraine attacks with or without aura, as diagnosed by International Classification of Headache Disorders (ICHD) criteria.
- Administration Window: Exactly 24 hours following the onset of a migraine headache attack or 24 hours post-administration of acute migraine pharmacotherapy.
- Item Count: 15 items, distributed evenly as 3 items per domain across 5 clinical domains.
- Domains Assessed:
- Work Functioning (Items 1–3)
- Social Functioning (Items 4–6)
- Energy / Vitality (Items 7–9)
- Migraine Symptoms (Items 10–12)
- Feelings / Concerns (Items 13–15)
- Response Format: 7-point Likert-type scale for each item, typically anchored from 1 (indicating the most severe degree of impairment, limitation, or symptom distress) to 7 (indicating no impairment, optimal functioning, or total absence of symptoms).
- Completion Time: Approximately 3 to 5 minutes, minimizing patient fatigue during the acute or postdromal migraine phase.
- Scoring Rules:
- Domain Scores: Calculated by taking the sum or mean of the 3 items comprising each respective subscale. Mean domain scores range from 1.0 to 7.0.
- Total Score: Calculated as the unweighted mean or sum across all 15 items. When transformed to a standard 0–100 scale, higher scores reflect superior health-related quality of life and complete functional recovery.
- Directionality: In the original scoring rubric established by Hartmaier et al. (1995), lower raw scores signify greater negative impact and severe disability, whereas higher scores denote preservation or full restoration of functioning.
- Missing Data Handling: If more than one item in a 3-item subscale is omitted, the subscale is considered invalid. If a single item is missing, the mean of the remaining two items may be imputed for the domain score.
11. Permissions & Fee and Test Year
The 24-Hour Migraine-specific Quality of Life Questionnaire was originally published in 1995 by Sara L. Hartmaier and colleagues, developed in part through clinical outcomes research initiatives at Merck Research Laboratories. The instrument, its structural framework, and its proprietary question items are protected by copyright held by the original authors and corporate research sponsors.
While the conceptual domains and scoring protocols are documented across peer-reviewed clinical literature for academic reference, the official questionnaire forms and permission for deployment in clinical trials, commercially sponsored research, or health software applications require formal authorization. Academic researchers and clinical investigators wishing to obtain the validated instrument, electronic adaptations, or certified foreign translations should contact the copyright holders, relevant HEOR corporate departments, or review licensing through designated health outcome assessment distributors. Fees may be waived for independent non-commercial academic research, whereas commercial and pharmaceutical clinical trial deployments typically require standard licensing agreements.
12. References
- Hartmaier, S. L., Santanello, N. C., Epstein, R. S., & Hollingworth, K. (1995). Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache: The Journal of Head and Face Pain, 35(6), 320–329. https://doi.org/10.1111/j.1526-4610.1995.hed3506320.x
- Santanello, N. C., Hartmaier, S. L., Epstein, R. S., & Silberstein, S. D. (1997). Validation of a 24-hour migraine-specific quality of life questionnaire for use in acute therapy trials. Headache: The Journal of Head and Face Pain, 37(6), 358–366. https://doi.org/10.1046/j.1526-4610.1997.3706358.x
- Silberstein, S. D., Santanello, N. C., Hartmaier, S. L., & Massiou, H. (1998). Responsiveness of the 24-Hour Migraine-Quality of Life Questionnaire in acute clinical trials. Cephalalgia, 18(9), 633–640. https://doi.org/10.1046/j.1468-2982.1998.1809633.x
- Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037